Citations

Showing 10 of 108081 citations.

Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction.
Redgrave, Rachael E. , Dookun, Emily , Booth, Laura , Folaranm, Omowumi, Tual‐Chalot, Simon , Passos, João F. , Richardson, Gavin D. , Passos, Joao, Richardson, Gavin D , Passos, João F , Gill, Jason H. , Owens, W. Andrew , Spyridopoulos, Ioakim

Mayo Clinic

No container title available | April 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2776501/v1 | PMID 37090497 Get It

Abstract Myocardial infarction is a leading cause of morbidity and mortality. While reperfusion is now standard therapy, pathological remodeling leading to heart failure remains a clinical problem. Cellular senescence has been shown to contribute to disease pathophysiology and treatment with the senolytic navitoclax attenuates inflammation, reduces adverse myocardial remodeling and results in improved functional recovery. However, it remains unclear which senescent cell populations contribute to these processes. To identify whether senescent cardiomyocytes contribute to disease pathophysiology post-myocardial infarction, we established a transgenic model in which p16 (CDKN2A) expression was specifically knocked-out in the cardiomyocyte population. Following myocardial infarction, mice lacking cardiomyocyte p16 expression demonstrated no difference in cardiomyocyte hypertrophy but exhibited improved cardiac function and significantly reduced scar size in comparison to control animals. This data demonstrates that senescent cardiomyocytes participate in pathological myocardial remodeling. Importantly, inhibition of cardiomyocyte senescence led to reduced senescence-associated inflammation and decreased senescence-associated markers within other myocardial lineages, consistent with the hypothesis that cardiomyocytes promote pathological remodeling by spreading senescence to other cell-types. Collectively this study presents a novel demonstration that senescent cardiomyocytes are major contributors to myocardial remodeling and dysfunction following a myocardial infarction. Therefore, to maximize the potential for clinical translation, it is important to further understand the mechanisms underlying cardiomyocyte senescence and how to optimize senolytic strategies to target this cell lineage.
Utility of a Smartphone Application in Assessing Palmar Circulation Before Radial Artery Harvesting for Coronary Artery Bypass Grafting
Parlow, Simon , Santo, Pietro Di , Abdel‐Razek, Omar , Jung, Richard G. , Motazedian, Pouya , Feagan, Hannah, Morgan, Baylie , Wade, Jilliane, Toeg, Hadi , Al‐Atassi, Talal , Kuhar, Peter , Bernick, Jordan , Wells, George A. , Froeschl, Michael , Mathew, Rebecca , Labinaz, Marino , Hibbert, Benjamin , Hibbert, Benjamin , Robinson, Lisa, Ruel, Marc , Simard, Trevor , Marbach, Jeffrey A. , Chan, Vincent

Mayo Clinic

Circulation | April 10, 2023 | Volume: 147 | Issue: 15 | Pages: 1183-1185

10.1161/circulationaha.122.063795 | PMID 37036908 Get It

“Not All That Fistulizes Is Crohn's Disease”: A Rare Case of Ischemic Jejunocolic Fistula
Gala, Khushboo , Ghusn, Wissam , Chedid, Victor , Ghusn, Wissam , Chedid, Victor G

Mayo Clinic

ACG Case Reports Journal | April 10, 2023 | Volume: 10 | Issue: 4 | Pages: e01021

10.14309/crj.0000000000001021 | PMID 37057193 Get It

ABSTRACT Enterocolic fistulae lead to abnormal diversion of gastrointestinal contents from the small intestine to the colon, causing diarrhea and protein energy malnutrition. We describe a rare case of a 40-year-old patient presenting with chronic diarrhea, unintentional weight loss, sitophobia, and severe abdominal pain in the setting of extensive thrombosis due to JAK2 V617F mutant disorder and associated tobacco use. Computed tomography enterography demonstrated an enterocolic fistula (jejunum to cecum), and a colonoscopy confirmed a 4 mm fistula in the cecum. The patient was nutritionally optimized with plans for a surgical fistula takedown in the future.
CHANGES IN VASOACTIVE DRUG REQUIREMENTS AND MORTALITY IN CARDIAC INTENSIVE CARE UNIT PATIENTS
Patel, Parag C. , Barsness, Gregory W. , Jentzer, Jacob C. , Diepen, Sean van , Morrow, David A. , Kashani, Kianoush

Mayo Clinic

Shock | April 10, 2023 | Volume: 59 | Issue: 6 | Pages: 864-870

10.1097/shk.0000000000002123 | PMID 37037002 Get It

ABSTRACT Background: The Society for Cardiovascular Angiography and Intervention (SCAI) Shock Classification can define shock severity. We evaluated the vasoactive-inotropic score (VIS) combined with the SCAI Shock Classification for mortality risk stratification. Methods: This was a single-center retrospective cohort analysis including Mayo Clinic cardiac intensive care unit patients from 2007 to 2015. The peak VIS was calculated at 1 and 24 h after cardiac intensive care unit admission. In-hospital mortality was evaluated using multivariable logistic regression. Results: Of 9,916 included patients, vasoactive drugs were used in 875 (8.8%) within 1 h and 2,196 (22.1%) within 24 h. A total of 888 patients (9.0%) died during hospitalization. Patients who required vasoactive drugs within 1 h had higher in-hospital mortality (adjusted odds ratio [OR], 1.30; 95% confidence interval [CI], 1.03–1.65; P = 0.03) and in-hospital mortality rose with the VIS during the first 1 h (adjusted OR per 10 units, 1.22; 95% CI, 1.12–1.33; P < 0.001). The increase in VIS from 1 to 24 h was associated with higher in-hospital mortality (adjusted OR per 10 units, 1.16; 95% CI, 1.10–1.21; P < 0.001). These results were consistent in the 1,067 patients (10.9%) with cardiogenic shock. A gradient of in-hospital mortality was observed according to the VIS at 1 h and the increase in VIS from 1 to 24 h. Conclusions: Higher vasoactive drug requirements portend a higher risk of mortality, particularly a high VIS early after admission. The VIS provides incremental prognostic information beyond the SCAI Shock Classification, emphasizing the continuum of risk that exists across the spectrum of shock severity.
STAT2 hinders STING intracellular trafficking and reshapes its activation in response to DNA damage
Wang, Chenyao , Holvey-Bates, Elise, Wightman, Samantha M. , Latif, Muhammad-Bilal, Zhao, Junjie , Li, Xiaoxia , Sen, Ganes C. , Stark, George R. , Wang, Yuxin , Wightman, Samantha , Sen, Ganes C , Stark, George R , Wang, Yuxin , Jing, Nan , Chen, Xing

Mayo Clinic

Proceedings of the National Academy of Sciences | April 10, 2023 | Volume: 120 | Issue: 16 | Pages: No page available

10.1073/pnas.2216953120 | PMID 37036972 Get It

In cancer cells, endogenous or therapy-induced DNA damage leads to the abnormal presence of DNA in the cytoplasm, which triggers the activation of cGAS (cyclic GMP–AMP synthase) and STING (stimulator of interferon genes). STAT2 suppresses the cGAMP-induced expression of IRF3-dependent genes by binding to STING, blocking its intracellular trafficking, which is essential for the full response to STING activation. STAT2 reshapes STING signaling by inhibiting the induction of IRF3-dependent, but not NF-κB–dependent genes. This noncanonical activity of STAT2 is regulated independently of its tyrosine phosphorylation but does depend on the phosphorylation of threonine 404, which promotes the formation of a STAT2:STING complex that keeps STING bound to the endoplasmic reticulum (ER) and increases resistance to DNA damage. We conclude that STAT2 is a key negative intracellular regulator of STING, a function that is quite distinct from its function as a transcription factor.
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America
Khalili, Mandana , Leonard, Kelsey R., Roberts, Lewis R. , Sterling, Richard K. , Belle, Steven H., Lau, Daryl , Chung, Raymond , Bisceglie, Adrian M. Di , Lisker‐Melman, Mauricio , Juan, Joshua, Yim, Colina, Lee, William M. , Murakam, Carol S., Perrillo, Robert, Do, Son , Han, Steven‐Huy B. , Tran, Tram T. , Cooper, Stewart , Tsai, Naoky, Younoszai, Barak, Fried, Michael, Darling, Jama M., Carithers, Robert C., Shuhart, Margaret C., Wang, Chia C. , Luketic, Velimir A. , Hoofnagle, Jay H., Doo, Edward , Park, Jang‐June , Roberts, Lewis R , Khalili, Mandana , Ghany, Marc G. , Hassan, Mohamed Ahmed Salih , Lok, Anna S. , Janssen, Harry L.A. , Wong, David , Feld, Jordan J. , Terrault, Norah A. , Fontana, Robert J. , Muir, Andrew Joseph , Evon, Donna M. , Kowdley, Kris V. , Liang, T. Jake , Chang, Kyong‐Mi , Wahed, Abdus S. , King, Wendy C. , Kleiner, David Erwin

Mayo Clinic

JAMA Network Open | April 10, 2023 | Volume: 6 | Issue: 4 | Pages: e237018

10.1001/jamanetworkopen.2023.7018 | PMID 37036707 Get It

ImportanceDisparities in treatment initiation may affect outcomes, but data on racially diverse populations with chronic hepatitis B virus (HBV) infection are limited.ObjectiveTo examine whether HBV treatment initiation and outcomes differ among racial groups.Design, Setting, and ParticipantsFrom January 14, 2011, to January 28, 2018, hepatitis B surface antigen—positive adults (age ≥18 years) not receiving anti-HBV therapy were enrolled and followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal cohort study (Hepatitis B Research Network [HBRN] adult cohort study) conducted in North America. The last study visit and data collection were completed January 28, 2019. Data were analyzed from August 27, 2021, to August 25, 2022. All HBRN participants were included unless they had acute HBV, HIV, hepatitis C or D, less than 24-weeks of follow-up after enrollment, initiated treatment at or immediately after enrollment, or had unknown race.ExposuresParticipants had clinical and laboratory assessments and could receive anti-HBV treatment after enrollment.Main Outcomes and MeasuresHepatitis B virus treatment initiation and major adverse liver outcomes (hepatic decompensation, hepatocellular carcinoma, liver transplant, and death).ResultsOf 1550 participants, 193 (12%) were African American or Black, 1157 (75%) were Asian, 157 (10%) were White, and 43 (3%) were other races; 789 (51%) were women, and the median age was 41.2 (IQR, 32.9-51.6) years. Sociodemographic and virologic parameters differed between groups. During 5727 person-years of follow-up, 504 participants initiated treatment, with incidences of 4.8 per 100 person-years in African American or Black individuals, 9.9 per 100 person-years in Asian individuals, 6.6 per 100 person-years in White individuals, and 7.9 per 100 person-years in those of other races (P &amp;lt; .001). A lower proportion (14%) of African American or Black participants met treatment criteria compared with Asian (22%) and White (27%) individuals (P = .01). The cumulative probabilities of treatment initiation after meeting the criteria were not significantly different among racial groups (African American or Black, 0.45; Asian, 0.38; White, 0.40 at 48 weeks and African American or Black, 0.45; Asian, 0.51; White, 0.51 at 72 weeks; P = .68). The incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.Conclusions and RelevanceIn this observational study of chronic HBV, African American or Black participants were less likely than individuals of other races to meet treatment criteria, but among those who did, HBV treatment receipt did not differ significantly by race or socioeconomic factors. Not all eligible participants initiated treatment, but adverse liver outcomes were rare. These findings may not be generalizable to patients with chronic HBV receiving care in other settings.
Surveillance of the Initiation of, Participation in, and Completion of Cardiac Rehabilitation in Minnesota, 2017–2018
Peacock, James M. , Styles, Emily , Johnson, Sara S. , Galos, Dylan L., Frumholtz, Mateo , Leth, Shawn , Pergolski, Aaron, Johnson, Sara

Mayo Clinic

Preventing Chronic Disease | April 10, 2023 | Volume: 20 | Issue: No issue available | Pages: No page available

10.5888/pcd20.220324 | PMID 37055156 Get It

Mechanism of KMT5B haploinsufficiency in neurodevelopment in humans and mice
Sheppard, Sarah E. , Bryant, Laura , Wickramasekara, Rochelle N. , Vaccaro, Courtney, Robertson, Brynn, Hallgren, Jodi , Hulen, Jason, Watson, Cynthia J., Faùndes, Víctor , Duffourd, Yannis , Simon, M. Celeste , Cruz, Xavier de la , Padilla, Natàlia , Flores‐Méndez, Marco , Akizu, Naiara, Smiler, Jacqueline , Silva, Renata Pellegrino da, March, Michael , Diaz‐Rosado, Abdias , Barcelos, Isabella Peixoto de , Choa, Zhao Xiang, Dubourg, Christèle , Journel, Hubert, Démurger, Florence , Mulhern, Maureen , Akman, Cigdem I. , Lippa, Natalie , Baldridge, Dustin , Haeringen, Arie van , Snoeck-Streef, Irina, Chow, Penny , Hing, Anne , Graham, John M. , Faivre, Laurence , Shen, Wei , Mao, Rong , Palumbos, Janice C. , Viskochil, David , Gahl, William A. , Hauser, Natalie , Miller, Rebecca L. , Maffeo, Jessica, Afenjar, Alexandra , Doummar, Diane , Keren, Boris , Macklin‐Mantia, Sarah K. , Meerschaut, Ilse , Zweier, Christiane , Brewer, Carole, Saggar, Anand, Smeland, Marie Falkenberg , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu, Nizon, Mathilde , Ierland, Yvette van , Wilke, Martina , Slegtenhorst, Marjon van, Koudijs, Suzanne M., Chen, Jin Yun, Dredge, David, Pier, Danielle B. , Wortmann, Saskia B. , Kamsteeg, Erik‐Jan , Koch, Johannes , Haynes, Devon , Pollack, Lynda, Titheradge, Hannah , Ranguin, Kara , Denommé‐Pichon, Anne‐Sophie , Weber, Sacha , Fuente, Rubén Pérez de la , Pozo, Jaime Sánchez del, Rosales, José Miguel Lezana , Joset, Pascal , Steindl, Katharina , Mei, Davide , Lespinasse, James, Philippe, Christophe , Dauriat, Benjamin, Raymond, Laure , Cueto‐González, Anna M. , Mignot, Cyril , Grotto, Sarah, Renaldo, Florence , Drivas, Theodore G. , Hennessy, Laura , Parenti, Ilaria , Kaiser, Frank J., Kuechler, Alma, Busk, Øyvind L. , Islam, Lily, Siedlik, Jacob A. , Henderson, Lindsay B. , Juusola, Jane, Person, Richard, Schnur, Rhonda E. , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth , Stessman, Holly A.F. , Lee, Pearl , Simon, M Celeste , de la Cruz, Xavier , Padilla, Natália , Flores-Mendez, Marco , Akizu, Naiara , Smiler, Jacqueline , Li, Dong , March, Michael , Peixoto de Barcelos, Isabella , Choa, Zhao Xiang , Lim, Chin Yan , Dubourg, Christèle , Mulhern, Maureen , Lippa, Natalie , Andrews, Marisa , Baldridge, Dustin , Constantino, John , Chow, Penny , Faivre, Laurence , Shen, Wei , Palumbos, Janice , Gahl, William , Tifft, Cynthia , Macnamara, Ellen , Keren, Boris , Macklin, Sarah , Meerschaut, Ilse , Callewaert, Bert , Reis, André , Smeland, Marie F , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu , van Ierland, Yvette , Wilke, Martina , Koudijs, Suzanne , Pier, Danielle , Wortmann, Saskia , Kamsteeg, Erik-Jan , Haynes, Devon , Titheradge, Hannah , Ranguin, Kara , Denommé-Pichon, Anne-Sophie , Weber, Sacha , Pérez de la Fuente, Rubén , Lezana Rosales, Jose Miguel , Steindl, Katharina , Rauch, Anita , Mei, Davide , Mari, Francesco , Guerrini, Renzo , Tran Mau-Them, Frederic , Moutton, Sébastien , Cueto-González, Anna M , Drivas, Theodore G , Parenti, Ilaria , Busk, Øyvind L , Siedlik, Jacob A , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth J , Stessman, Holly A F , Sheppard, Sarah E; https://orcid.org/0000-0003-3480-8123, Bryant, Laura; https://orcid.org/0000-0001-8483-8940, Wickramasekara, Rochelle N; https://orcid.org/0000-0003-3090-9357, Lee, Pearl; https://orcid.org/0000-0002-1274-2891, Simon, M Celeste; https://orcid.org/0000-0001-9106-447X, Padilla, Natália; https://orcid.org/0000-0002-7872-2279, Akizu, Naiara; https://orcid.org/0000-0001-9222-6960, Li, Dong; https://orcid.org/0000-0002-2265-6727, March, Michael; https://orcid.org/0000-0001-9173-6862, Barcelos, Isabella Peixoto; https://orcid.org/0000-0002-3843-4520 de, Choa, Zhao Xiang; https://orcid.org/0000-0002-1838-7931, Lim, Chin Yan; https://orcid.org/0000-0002-1585-002X, Mulhern, Maureen; https://orcid.org/0000-0001-8642-4741, Joset, Pascal; https://orcid.org/0000-0002-4349-9951, Steindl, Katharina; https://orcid.org/0000-0002-4425-3072, Rauch, Anita , al, et

Mayo Clinic

Science Advances | April 10, 2023 | Volume: 9 | Issue: 10 | Pages: No page available

10.1126/sciadv.ade1463 | PMID 36897941 Get It

Pathogenic variants in KMT5B , a lysine methyltransferase, are associated with global developmental delay, macrocephaly, autism, and congenital anomalies (OMIM # 617788). Given the relatively recent discovery of this disorder, it has not been fully characterized. Deep phenotyping of the largest ( n = 43) patient cohort to date identified that hypotonia and congenital heart defects are prominent features that were previously not associated with this syndrome. Both missense variants and putative loss-of-function variants resulted in slow growth in patient-derived cell lines. KMT5B homozygous knockout mice were smaller in size than their wild-type littermates but did not have significantly smaller brains, suggesting relative macrocephaly, also noted as a prominent clinical feature. RNA sequencing of patient lymphoblasts and Kmt5b haploinsufficient mouse brains identified differentially expressed pathways associated with nervous system development and function including axon guidance signaling. Overall, we identified additional pathogenic variants and clinical features in KMT5B -related neurodevelopmental disorder and provide insights into the molecular mechanisms of the disorder using multiple model systems.
Obesity and vascular complication in percutaneous transfemoral transcatheter aortic valve insertion
Hosseini, Motahar , Lahr, Brian D. , Greason, Kevin L. , Gulati, Rajiv , Eleid, Mackram F. , Eleid, Mackram F , Hosseini, Motahar , Arghami, Arman , Crestanello, Juan A.

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 10, 2023 | Volume: 101 | Issue: 7 | Pages: 1221-1228

10.1002/ccd.30658 | PMID 37036273 Get It

AbstractBackgroundObesity has been associated with an increased risk of vascular complication during percutaneous coronary intervention, but there are no data on the risk of vascular complication during percutaneous transfemoral transcatheter aortic valve insertion (TAVI).ObjectivesWe hypothesized there would be a similar increased risk associated with TAVI.MethodsWe reviewed the records of 1176 patients who received percutaneous transfemoral transcatheter aortic valve insertion from September 2015 to September 2020. All patients received 1) preoperative computed tomoraphy angiography assessment of the abdomen and pelvis to delineate iliofemoral artery anatomy, 2) ultrasound‐guided percutaneous femoral arterial access, and 3) pre‐closure of the delivery sheath femoral access site. Vascular complication was recorded based on definitions set forth by Valve Academic Research Consortium 3.ResultsThe median age of patients was 81 years, and 60% were men. The median body mass index (BMI) was 29 kg/m2 (range, 11–67), and 91 (8%) patients had a value ≥40 kg/m2 (i.e., morbid obesity). Delivery sheath size was 14‐French in 859 (73%) patients, 16‐French in 311 (26%), and 18‐French in 6 (1%). Vascular complication occurred in 53 (5%) patients, including 39 (7%) among the first half of procedures and 14 (2%) among the second half (p < 0.001). When stratified by obesity status (BMI < or ≥30 kg/m2, p < 0.001), the complication rate was 4% in nonobese patients and 5% in obese patients. Multivariable analysis showed no overall association between risk of vascular complication and BMI categories (p = 0.583)BMI continuous values (p = 0.529), or sheath size (p = 0.217).ConclusionsObesity is not associated with a vascular complication during percutaneous transfemoral transcatheter aortic valve insertion. The operation should not be denied in obese patients.
Neoadjuvant Therapy Regimens for Hilar Cholangiocarcinoma Before Liver Transplant
Keltner, Samuel J. , Hallemeier, Christopher L. , Tao, Randa , Kharofa, Jordan , Hallemeier, Christopher, Tao, Randa , Hallemeier, Christopher Leigh , Wang, Kyle , Shah, Shimul A. , Heimbach, Julie K.

Mayo Clinic

American Journal of Clinical Oncology | April 10, 2023 | Volume: 46 | Issue: 6 | Pages: 276-278

10.1097/coc.0000000000001002 | PMID 37036238 Get It

Objectives: Patients with unresectable hilar cholangiocarcinoma (hCCA) may be eligible for curative treatment through liver transplantation (LT). Neoadjuvant protocols often include radiotherapy (RT), however, there is no standard RT approach. The purpose of this study is to characterize practice patterns of RT use before transplantation for hCCA. Methods: A survey was administered to radiation oncologists practicing at LT centers identified through the U.S. Organ Procurement and Transplant Network and the International Cholangiocarcinoma Research Network. The survey consisted of 13 questions regarding RT details as well as approaches to systemic therapy. For cross-regimen comparison, the cumulative RT tumor dose was standardized using the EQD2 method. Results: Twenty-three centers utilizing neoadjuvant therapy for hCCA were identified. Most respondents (96%) use both chemotherapy and RT as part of their protocol. Elective nodal volumes commonly included the portal vein lymph nodes (91%) and celiac artery lymph nodes (70%). After an initial 45 Gy plan, a wide range of sequential boost regimens was used. The median cumulative dose including boosts to the gross disease was 58 Gy (EQD2) with a wide range of 40 to 110 Gy. Five (22%) include brachytherapy as part of their treatment plan. The majority (96%) used concurrent chemotherapy with fluoropyrimidines. Conclusions: These results suggest significant variability of neoadjuvant RT use for hCCA before LT. A wide range of doses and fractionation schemes are utilized with cumulative doses ranging from 40 to 110 Gy (EQD2). A further study evaluating the efficacy and toxicity of these various approaches is warranted to better inform best practices.